<![CDATA[The Next Wave of Obesity Drugs - Opportunities and risk]]>GLP-1 weight loss drugs Wegovy® (semaglutide) and Zepbound® (tirzepatide) from Novo Nordisk and Eli Lilly hit markets like a tsunami, when they were approved in June 2021 and November 2023, due to their unprecedented weight-loss efficacy

The next waves might not be as colossal, but they still hold potential for investors navigating these waters.

Læs hele blogindlægget fra Tommy Carstensen

https://blog.midgardfinance.com/2025/01/26/the-next-wave-of-obesity-drugs-opportunities-and-risks-for-investors/

]]>https://dev.proinvestor.com/forum/topic/447024/the-next-wave-of-obesity-drugs-opportunities-and-riskRSS for NodeSun, 14 Jun 2026 18:00:24 GMTWed, 29 Jan 2025 04:35:44 GMT60